<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634595</url>
  </required_header>
  <id_info>
    <org_study_id>TG0717E10A</org_study_id>
    <nct_id>NCT00634595</nct_id>
  </id_info>
  <brief_title>Trial of E10A in Head and Neck Cancer</brief_title>
  <official_title>A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doublle Bioproduct Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiogenesis, the formation of new blood vessel from existing vessels, is essential for tumor
      growth and metastasis. Antiangiogenic therapies inhibit the growth of genetically stable
      endothelial cells, and most tumors should starve to death with little acquired resistance.
      Endostatin has been shown to block endothelial cell proliferation, survival, and migration.
      Antitumor activity of endostatin protein has been demonstrated in various murine and human
      tumors in animal model studies without any detectable toxicity. Endostatin gene therapy could
      directly express the highly bioactive protein in vivo by means of the mechanism of eukaryotic
      expression system as post-translational modification and folding, as well as overcoming the
      challenge of the long-term storage and the cumbersome daily administration of endostatin
      protein.

      E10A is a replication-deficient recombinant adenovirus containing a wild-type human
      endostatin transgene constructed from serotype 5 adenovirus (Ad5). Preclinical studies
      demonstrated that intratumoral injection of E10A provided significant tumor growth inhibition
      and sustained elevation of endostatin in blood and tumor tissue in hepatocellular carcinoma,
      nasopharyngeal carcinoma, and tongue cancer animal models. A Phase I clinical trial of E10A
      we conducted showed that repetitive intratumoral injection of E10A resulted in a small and
      sustained elevation of endostatin in blood and had a mild antitumor activities with very
      limited toxicity. The major toxicity was transient and manageable fever. A randomized Phase
      III trial in nonsmall-cell lung cancer showed endostatin improved response rate and time to
      tumor progression in combination to chemotherapy. Therefore, we designed a randomized phase
      II trial to explore the safety and effectiveness of E10A combined with chemotherapy in the
      treatment of patients with head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response confirmed by CT or MRI</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NCI toxicity criteria (CIC 3.0)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Head and Neck Squamous Carcinoma</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E10A combined with Cisplatin and Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin and Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E10A</intervention_name>
    <description>E10A 1*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed recurrent or metastatic head and neck
             squamous carcinoma or nasopharyngeal carcinoma

          -  the tumor was amenable to direct injection and measurement ( &gt; 2 cm)

          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  a life expectancy over three months

          -  the absence of serious medical or psychiatric disorders

          -  serum creatinine &lt; 1.5 mg/dL; WBC count &gt;3,000/mm3, platelet count &gt; 80,000/mm3,
             hemoglobin &gt; 8 g/dL; total bilirubin value &lt; 1.5 times the upper limit of normal
             [ULN], ALT level &lt; 2.5 times ULN, AST &lt; 2.5 times ULN.

        Exclusion Criteria:

          -  pregnant or breast feeding

          -  a history of brain metastases or a primary brain tumor

          -  a history of hemorrhagic diathesis

          -  a history of corticosteroids or immunosuppressives use within four weeks of study
             entry

          -  a history of immune deficiency disorder or organ transplant

          -  has evidence of active adenovirus infection or uncontrolled infection

          -  received any chemotherapy or radiotherapy within four weeks of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenqi Jiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xubin Lin, MD, PhD</last_name>
    <phone>86-20-87343355</phone>
    <email>linxubin@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xubin Lin, MD, PhD</last_name>
      <email>linxubin@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lin X, Huang H, Li S, Li H, Li Y, Cao Y, Zhang D, Xia Y, Guo Y, Huang W, Jiang W. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther. 2007 May;6(5):648-53. Epub 2007 Feb 13.</citation>
    <PMID>17426445</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>July 26, 2010</last_update_submitted>
  <last_update_submitted_qc>July 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wenqi Jiang, Professor</name_title>
    <organization>Cancer center, Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>randomized</keyword>
  <keyword>Endostatin</keyword>
  <keyword>gene therapy</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>head and neck squamous carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

